MLTO Medirect Latino Inc (CE)

MEDirect Latino Inc. (OTC:MLTO) - http://www.medirectlatino.org -, the leading provider of medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico, today announced the retaining of the Law Firm of Melissa K. Rice, P.A. to file the Company's Form 10-SB Registration, making the Company fully reporting with the Securities Exchange Commission (SEC). Such filing is to be made with the SEC by the end of June 2005. The Law Firm of Melissa K. Rice, P.A. concentrates in the areas of the representation of small to medium sized companies, and specializes in regulatory compliance with agencies, such as the SEC. MEDirect Latino is currently trading on the Pink Sheets, under the symbol MLTO. Upon the effective date of the Form 10-SB filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. It is contemplated that reporting status will be achieved no later than September 2005, with the Company then attaining a listing on the Electronic Bulletin Board, which is a regulated market for small reporting companies. Upon attaining reporting status, the Company will also file a listing application with the NASD to be listed on the NASDAQ Stock Exchange. It is anticipated by the management of MEDirect that a listing on NASDAQ will be attained no later than the first quarter of 2006. "Revenues developed as a result of the Company's successful expansion of operations in Puerto Rico, coupled with the national television advertising launch of our products and services in July, plus the increasing broker/dealer and institutional interest in MLTO, are the key drivers in MEDirect Latino's Form 10-SB filing. Corporately, we are months ahead of our 2005 strategic business plan," stated MEDirect Latino CEO and Co-Chairman, Raymond J. Talarico. Further, stated Mr. Talarico, "This registration will allow for deeper institutional investment in MLTO and a lower cost of capital to sustain our national launch of our products and services which will begin in July, 2005. Despite initially listing on the Pink Sheets, we have full GAAP audits for our last two fiscal years, and we maintain all corporate governance requirements for a listing on NASDAQ. Therefore our transition to reporting status should be seamless." A free independent corporate analysis of MEDirect Latino Inc., which includes information on the Company's business model, products, industry, valuation, management, and risks, and reaches the conclusion of an initial short term price target of $8 per share is available at http://www.wallstreetresources.net/pdf/fc/MLTO.pdf MEDirect Latino completed an investor conference call on Tuesday, May 17, 2005. To hear a recording of the call: -0- *T Call 1-800-977-8002 in the United States or Canada or; Call 1-404-920-6650 in the Atlanta Area or Internationally Pin Code: Press the star key then 098756 *T The Company will be holding another investor call on Tuesday, June 28th where management will discuss the results of its expanded operations in Puerto Rico, its national launch of its products and services in July, 2005, and several joint ventures and private label manufacturing agreements, which will expand the products offered by the Company to the Hispanic marketplace. About MEDirect Latino: MEDirect Latino (OTC:MLTO), http://www.medirectlatino.org, is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure. The current Hispanic market for MEDirect's products is conservatively estimated at approximately $650MM in the continental United States. The size of the opportunity is understated by such figures as an estimated 925,000 of the over 3.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion) Forward Looking Statements: Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this press release; the Company will appropriately inform the public.